Develops targeted therapies for rare diseases and oncology, focusing on improving patient outcomes through innovative treatments.
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering therapies for cancer and rare diseases. Headquartered in New York, New York, the company is dedicated to discovering and advancing transformative treatments that address significant medical challenges.
The cornerstone of Protara's pipeline is TARA-002, an investigational cell therapy designed for the treatment of lymphatic malformations. This innovative program underscores Protara's commitment to leveraging cutting-edge technology to tackle complex conditions with high unmet needs. Additionally, the company is developing intravenous choline chloride, an investigational therapy aimed at replacing phospholipid substrates to address intestinal failure associated liver disease.
Founded as ArTara Therapeutics, Inc. and rebranded as Protara Therapeutics, Inc. in May 2020, the company has positioned itself at the forefront of biopharmaceutical innovation. With a strong focus on advancing novel therapies through clinical trials and strategic partnerships, Protara Therapeutics continues to push boundaries in the quest to improve patient outcomes worldwide.